BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Business

  RedHill Biopharma Reports 2017 Third Quarter Financial Results

  RedHill maintains a debt-free balance sheet with $39.6 million in cash1 at the end of the third quarter of 2017.

  November 13, 2017

   · 

  31 min read
• Pharm Country

  Creative Peptides Newly Diversified Its Special Antigen Peptides Services

  On October 26, 2017, the leading peptides supplier Creative Peptides announced to further diversify its special antigen peptides services after entering this market for nearly a decade.

  November 13, 2017

   · 

  1 min read
• Policy

  Protalix BioTherapeutics Receives Positive Opinion for Orphan Designation for PRX-102 for the Treatment of Fabry Disease in the European Union

  In its official opinion letter, the COMP explained that Protalix has established that although satisfactory methods of treatment of Fabry disease have been authorized in the European Union, PRX-102 will be of significant benefit to those affected by Fabry disease.

  November 13, 2017

   · 

  7 min read
• Business

  Xbrane Biopharma Releases Interim Report for the Period July to September 2017

  nterim report for the period July - September 2017 is now available on the company’s website.

  November 13, 2017

   · 

  1 min read
• Drug Development

  Five Prime Therapeutics Presents Poster on FGFR2b Expression and Immune Signature in Urothelial Cancer at the Society for Immunotherapy of Cancer 32nd Annual Meeting

  Five Prime is developing FPA144, an isoform-selective antibody, as a targeted immunotherapy for tumors that overexpress FGFR2b.

  November 13, 2017

   · 

  3 min read
• Drug Development

  Three-Year Follow-Up Phase III Data Provide Additional Information on Efficacy, Durability and Safety Of Investigational LUXTURNA (Voretigene Neparvovec) in Patients With Biallelic RPE65-Mediated Inherited Retinal Disease

  Data show mean improvement demonstrated at one year post one-time administration maintained through at least three years for original intervention cohort, and two years for crossover cohort, with observation ongoing.

  November 13, 2017

   · 

  12 min read
• Drug Development

  Argos Therapeutics Provides Update on Immunology Data from the Phase III ADAPT Trial Presented at the SITC 2017 Annual Meeting

  The presentation is focused primarily upon immunology data from the ADAPT clinical trial and includes both new data and an update to data that was previously presented at the European Society of Medical Oncology Conference in September.

  November 13, 2017

   · 

  9 min read
• Genetown

  CRISPR Therapeutics Highlights New Additions to Portfolio of Allogeneic CRISPR-based CAR-T Therapies at SITC Annual Meeting

  CRISPR believes that its CAR-T cells therapies may have distinct advantages over the current generation of autologous cell therapies.

  November 13, 2017

   · 

  6 min read
• BioMidwest

  Merck Animal Health Announces Increase in Funding for Veterinary Student Scholarship Program

  Merck Animal Health has announced an increase of $115,000 in funding for its Veterinary Student Scholarship Program.

  November 13, 2017

   · 

  3 min read
• Business

  Orexigen Therapeutics Announces Third Quarter 2017 Financial Results

  Total operating expenses for the third quarter of 2017 were $37.6M compared to a credit of $37.5M for the third quarter of 2016.

  November 13, 2017

   · 

  24 min read